BrincDownload deck PDF

A*STAR × ENTERPRISE SINGAPORE · NOVEMBER 2026

Start with an eight-week validation Sprint

A proposal for A*STAR and Enterprise Singapore.

Before committing to a longer programme, test the Precision Health pipeline, venture opportunities and delivery requirements in Singapore.

Our proposal: A*STAR commissions an eight-week Design and Portfolio Validation Sprint. At week eight, review the evidence and decide whether to proceed with a separately approved 24-month venture-building pilot.

Working proposal · For review and confirmation

THE PROPOSED PATHWAY01 / 02
8weeks
Validate the
programme
First decision: commission the Sprint
Evidence review & separate pilot approval
24months
Venture-building
pilot
Only with separate approval after the Sprint
TRACK 01Form new
ventures
TRACK 02Grow existing
ventures

Singapore first. International recruitment is an optional, separately commissioned workstream.

75+programmes

260+portfolio companies

Brinc’s cumulative group credentialsExplore the specific work and supporting evidence below.

THE OPPORTUNITY

One assessment process for the Singapore pipeline

A*STAR contributes research assets and ventures. Enterprise Singapore mobilises eligible companies through its network. Brinc works with scientists and venture teams to test market gaps, develop venture plans and recruit entrepreneurial leadership.

Four connected focus areas

  1. 01Physical health and age-related function, including sarcopenia
  2. 02Brain health
  3. 03Gut–organ axis
  4. 04Socio-environmental factors

Preventive population health and healthy longevity.

BRINC’S PROPOSED CONTRIBUTION

Focus support on each venture’s next milestone

The Sprint maps the support already available to each project and identifies the work still needed. Brinc’s proposed role is to lead the agreed market validation, venture planning, founder matching and customer or capital preparation. Each plan identifies the responsible owner and handoffs to existing support.

The Sprint gives the agencies a decision package before committing to the pilot. During delivery, stage gates and quarterly reviews tie resources to the evidence and the next work each venture needs.

How Brinc works with the agencies ↗

A*STAR’S OUTCOME AMBITIONS

The targets and the work behind them

These are A*STAR’s stated outcome ambitions. Brinc is accountable for agreed service outputs, evidence quality, qualified introductions and delivery cadence. Venture outcomes also depend on scientific progress, founders, institutional decisions, customers and capital. The Sprint tests the delivery plan against these targets.

20–30 projects for potential spin-offs

Programme contribution

Assess A*STAR research assets and eligible Singapore referrals against common criteria. Prioritise opportunities by technology, IP, founder and market readiness.

Evidence to review

A deduplicated opportunity register with source, owner, readiness, evidence gaps and the next decision.

Definition and dependencies

Agree what qualifies as a potential spin-off project and establish the starting baseline. Referrals and assessments do not automatically count as qualified projects.

Supporting detail ↗
Ten spin-offs must each reach at least one threshold by August 2030
S$1msales revenueORS$10minvestmentORS$50mpost-money valuation

The alternatives are not cumulative requirements. Measurement period, eligible entity and evidence are agreed before reporting. A company meeting several thresholds counts once.

Up to 15 formation assessments per year, 8–10 validated theses across the pilot and 6–8 growth ventures active at a time are separate planning measures. They are not additive places or a forecast conversion funnel. The Sprint tests workload and staffing; achieving the additional ten spin-offs by August 2030 requires continued formation work and separately agreed resources. Capacity detail ↗

PROGRAMME

An eight-week Sprint to validate the plan

The first engagement is an eight-week validation Sprint. Brinc assesses the pipeline, tests venture pathways and develops the delivery and resource plan. By week eight, the agencies have an evidence-based recommendation to proceed, refine or pause. A 24-month pilot requires a separate approval.

SPRINT / 01

Objectives, owners and baseline

Align outcomes, owners, access and definitions. Map existing venture-support providers and record the pipeline and staffing baseline.

Output: Inception note, dependency register and diagnostic framework.

Workplan detail ↗
TRACK 01 / FORMATION

Turn research into
a venture thesis.

Assess the asset and market problem. Interview users and buyers, develop business-model options, match founders and prepare IP and formation milestones.

DELIVERABLE

Venture thesis, founder plan and formation-readiness pack.

Formation scope
TRACK 02 / GROWTH

Advance towards
customers and capital.

Diagnose readiness, build a focused customer and pilot pipeline, shape commercial success criteria and prepare investor narratives and data rooms.

DELIVERABLE

Commercial diagnostic, pilot or customer plan and next decision.

Growth scope
Optional international recruitment

Source and screen companies with a credible Singapore use case. Confirm local operating pathways and track evidenced landing milestones within a separate scope and capacity.

Optional workstream

PROGRAMME TIMELINE

From the Sprint to the 2030 outcomes

The eight-week Sprint and the 24-month pilot have separate clocks. Actual start dates remain to be agreed. The pilot sequence will be calibrated during the Sprint; existing ventures may progress earlier. August 2030 is a fixed outcome horizon, so the remaining time must be reassessed when mobilisation is agreed.

Select a phase to see the work, outputs and decision owners.

Before the Sprint

Confirm owners and access

Work

Confirm the commissioning route, signatory, start date, named delivery allocations, confidentiality arrangements and access to representative pipeline information.

Outputs

Named owners, deliverable reviewers, access arrangements and an agreed mobilisation plan.

Decision and owner

A*STAR’s commissioning authority and the relevant institutional owners confirm their responsibilities; Brinc confirms delivery coverage.

Contribution to the KPIs

Establish a reliable baseline and the resources needed to assess the pipeline.

Workplan detail ↗
1 / 12

Proposed delivery rhythm

FortnightlyWorking group and dependency review
MonthlyPortfolio reporting and founder or specialist sessions
QuarterlySteering reviews and curated commercial or investor roundtables
AnnuallyPortfolio review and showcase, with agreed event resources

These are proposed cadences, not booked calendar events. Regular mentor office hours complement the sessions; major event production and venue costs require separate agreement.

DELIVERY

Who delivers, decides and accepts the work

Brinc leads day-to-day execution. Agency and institutional owners retain the decisions within their remit.

A*STAR

Commission the Sprint; lead scientific intake and review; provide authorised pipeline access; retain research and IP authority.

Enterprise Singapore

Proposed co-organiser and ecosystem lead; mobilise eligible Singapore ventures, community participation and enterprise pathways.

Brinc

Assess and support ventures; coordinate specialists; build customer and capital readiness; maintain evidence and decision packs.

Working role model pending agency confirmation. Procurement, signatory, start date, contributions and actual allocations are confirmed before mobilisation. Full responsibility model

PLANNING CAPACITY

Capacity for assessment, formation and growth

15formation assessments
per year, up to
8–10validated theses
across the pilot
6–8growth ventures
active at a time

Distinct, non-additive planning assumptions, subject to Sprint validation of workload, budget and staffing. Optional recruitment requires its own resources.

DECISION RHYTHM

Delivery and review schedule

  • Fortnightly working group
  • Monthly portfolio reporting
  • Quarterly steering and portfolio reviews
  • One decision log and owner per action
Governance & authority
GATES

Stage gates and progression

Eligibility → deeper validation → formation or intensive growth → launch or pilot → scale readiness.

Hold and stop decisions record what is needed for reconsideration.

Gate decision rights
ACCEPTANCE

Review and acceptance

Named reviewers assess evidence and completeness. Institutional owners decide scientific and IP matters; the commissioning authority accepts contracted services.

Acceptance basis

PEOPLE

Singapore delivery and regional contributors

Brinc has an active Singapore network through its portfolio companies, investor relationships and mentors, alongside an established record of venture support and ecosystem activity. The two Singapore roles under recruitment and the named regional contributors are shown separately below.

SINGAPORE

Two Singapore roles
under recruitment.

Director, SingaporeLeadership and stakeholder alignment
Innovation ManagerDay-to-day delivery and portfolio coordination

Director, Singapore and Innovation Manager remain under recruitment. Appointments, availability and dedicated time must be confirmed before mobilisation.

Local coverage

LOCAL DELIVERY ROLES

Recruit against the work the portfolio needs.

Director, Singapore and Innovation Manager remain under recruitment. Appointments, availability and dedicated time must be confirmed before mobilisation.

Complementary responsibilities

The Director leads programme delivery and stakeholder decisions. The Innovation Manager coordinates venture work, evidence, community activity and follow-up. Clinical, regulatory and IP specialists are assigned separately.

Specialists follow venture needs

Clinical, regulatory, technical and IP coverage is assigned explicitly. Bipin Bhola’s historical Brinc MedTech role illustrates relevant experience; any contribution is separately agreed. His current affiliations do not establish programme partnerships. Historical Singapore contributors and matching records provide further examples; future specialist assignments remain separate. Explore historical contributors ↗

Specialist biography

SINGAPORE OPERATING EXPERIENCE

An established Singapore presence and venture-support track record

Brinc has an active Singapore network through its portfolio companies, investor relationships and mentors, alongside an established record of venture support and ecosystem activity. Dated examples below show founder preparation, mentoring, ecosystem visits and targeted matching with local collaborators. Programme participation will be agreed around the selected ventures’ needs.

How to read this evidence

These are historical activity records. The source does not distinguish scheduled, attended, completed or cancelled events. Entries do not establish completed clinical pilots, paid sales, institutional endorsement or future commitments.

Founder preparation and ecosystem engagement

3–4 November 2025

Incheon BioMedTech

Five startups; demo activity, one-to-one matching and host visits. A CHI / Tan Tock Seng Hospital clinical ecosystem visit is recorded in the programme window.

Recorded collaboratorsIncheon, Tap Angel, Alysium and Brinc Korea

Programme applicationPrepare founders for relevant counterpart conversations and ecosystem visits.

13–15 January 2026

Yonsei / Halla

KR-SG Pitch Challenge: pitch training, judges and Block71 / Tenity sessions.

Recorded collaboratorsIdea Partners, Alysium and Brinc Korea

Programme applicationCombine pitch preparation with feedback and ecosystem exposure.

3–5 February 2026

Pukyong-led immersion

Mentoring, SMU / Block71 tours, faculty exchange and pitch activity.

Recorded collaboratorsSeed Partners, Alysium and Brinc Korea

Programme applicationConnect university founders with relevant mentors and ecosystem input.

Programme records and qualifications

Historical collaborators and contributors

Affiliations and contributions are recorded at the time. These historical collaborators are separate from proposed staff and specialist appointments. Current affiliation, future involvement, responsibilities and allocated time require agreement.

Dated contributions and affiliations recorded in Singapore programme activity
ContributorAffiliation at the timeDated contribution
Allison Hui May NamAlysium / Nandina REM2024–26Co-programme development and delivery.
Edmas NeoAccrete InnovationMarch 2024Lecture, mentoring, judging and ecosystem activity. The programme entry names local organisers without explicitly naming Brinc.
Marc PaletVectr (2024); OMVC (2025–26)2024–26Judging and mentorship in 2024; sessions and matching in 2025; judging in 2026.
David HwanKadan CapitalJanuary, February and October 2026Repeated judging records.
Dorothy YuanProtégéJanuary–February 2026Judging records.
Contributor context

26–30 October 2026

TeX-Corps

The programme record lists seven startups, corporate and clinical matching, and a demo. The entries below illustrate matching around different venture questions.

Recorded collaboratorsAlysium, Brinc Korea and a Seed Partners contact

Recorded healthcare and research counterpart matching
CounterpartDateRecorded activity
National Neuroscience Institute27 October 2026Neuroscience counterpart matching
NTU / IMH / Centre for AI in Medicine27 October 2026AI-in-medicine counterpart matching; grouping retained as recorded
TÜV SÜD PSB28 October 2026Specialist counterpart matching
ClinActis28 October 2026Clinical-research counterpart matching

Matching records do not confirm attendance, completed pilots, purchased services or an appointed clinical advisory panel. Any new participation, responsibility and time must be agreed separately.

Matching context

How these methods inform the proposed community

Enterprise Singapore is proposed to lead ecosystem mobilisation. Brinc curates the programme around venture needs, prepares introductions and follows through. A*STAR brings research leads and domain specialists into relevant reviews. These working arrangements remain subject to A*STAR confirmation.

  1. Prepare around the venture’s question

    Record the commercial, technical or adoption question and prepare a brief before seeking an introduction.

  2. Agree the appropriate conversation

    Identify the relevant counterpart and confirm their interest, role and availability. Specialist authority remains with the appropriate professional or institution.

  3. Follow through to the next milestone

    Record the introduction, next action and owner. Measure qualified follow-up and venture progress separately from attendance, signed pilots and paid contracts.

Community roles, cadence and boundaries

EVIDENCE

Relevant experience in Singapore and beyond

Singapore research-origin ventures, MedTech precedents and dated programme activity lead the proposal. The Singapore examples above add founder preparation, mentoring and counterpart matching. Healthcare, Hong Kong and MENA cases add specific operating lessons. Historical relationships and company milestones do not establish future commitments.

25 / 197
12.7% of active companies Healthcare-tagged

Internal portfolio snapshot, 12 November 2026. Tags overlap; records are not founder-verified. This active subset is distinct from the cumulative 260+ portfolio credential.

Portfolio basis

14 selected examples

Research to venture

MyrLabs

A*STAR research origin. Brinc advisory and accelerator activity documented in 2020; later participation in an HKSTP landing cohort.

Relevance to this programmeWork with a research-origin team on venture development and opportunities in other markets.

Robotics · research commercialisation

Case & evidence

Nutrition and research

AuroraFood

NUS food-science spin-off with a functional-food proposition. Included in Brinc’s 2020 Hong Kong programme and investment portfolio.

Relevance to this programmeAssess IP, founder capacity, market validation and customer access, with specialists appropriate to the sector.

Nutrition adjacency · no clinical efficacy claim

Case & evidence

University-linked venture

Botsync

NTU-linked robotics company with early backing from Brinc. A Singapore university-linked venture example from outside healthcare.

Relevance to this programmeAssess IP, founder capacity, market validation and customer access, with specialists appropriate to the sector.

Robotics · no exit or current advisory commitment implied

Case & evidence

Founder development

CityUHK

Brinc delivered an eight-week programme for HK Tech 300’s first cohort, covering team formation, validation and venture readiness.

Relevance to this programmeStructure founder development and validation work around the formation track.

Historical delivery · further venture referrals in 2026

Case & evidence

Institutional history

NHIC

A March 2023 three-year MoU covered healthcare innovation, knowledge sharing and talent development.

Relevance to this programmeUnderstand the institutional work involved in healthcare research commercialisation.

Historical framework · renewed participation separately agreed

Case & evidence

Healthcare programmes

Future Health Asia

The 2021 Singapore–Hong Kong MedTech cohort included CAREFUL, Altris AI, SAMA and Healium Digital.

Relevance to this programmeDraw on a historical specialist MedTech programme and its cohort experience.

Programme and cohort evidence

Case & evidence

Named hospital activity

SmartPeep

Parkway East Hospital implementation and a Malaysian acute stroke-unit study are distinct company outcomes.

Relevance to this programmeExamine the user, site and evidence required for healthcare adoption. This is company activity; Brinc’s documented role was later portfolio reporting.

Implementation / study · paid sales not established

Case & evidence

Product evidence

Altris AI

Brinc / Future Health Asia cohort participant. Altris IMS clearance covers image management and manual annotation.

Relevance to this programmeCheck that product claims match the precise regulatory clearance.

K232088 · not AI diagnosis clearance

Case & evidence

Research pathway

Frontier Bio

A publicly described blood-vessel proof of concept with Mayo Clinic illustrates research-intensive commercialisation.

Relevance to this programmePlan the transition from research evidence to a credible commercial application.

Company research collaboration · not a sales claim

Case & evidence

Corporate innovation

Manulife BOOST

The 2021 announcement documents Brinc’s role in startup selection and proof-of-concept scoping.

Relevance to this programmeDefine the corporate challenge, select suitable ventures and scope a proof of concept.

Selection / scoping · no completed-pilot claim

Case & evidence

Venture development

Jetbrain

A 2018 Brinc accelerator participant acquired by Solaris in August 2020.

Relevance to this programmeSupport venture development while keeping acquisition outcomes separate from the service promise.

Hospital logistics · separate from disinfection technology

Case & evidence

Institutional delivery

startAD

Brinc’s 2025 AI Readiness Track covered needs assessment, challenge definition and solution evaluation.

Relevance to this programmeTurn an organisation’s needs into defined challenges, solution assessments and pilot plans.

Workshops and pilot roadmaps

Case & evidence

Research commercialisation

TRL Bridging

Workshops and individual mentoring supported research teams entering industry engagement.

Relevance to this programmeHelp research teams prepare for industry engagement through workshops and individual mentoring.

Khalifa University / ADGM Academy

Case & evidence

Government programmes

MBRIF

A government-backed venture-growth precedent combining practical commercial support and ecosystem connections.

Relevance to this programmeCoordinate commercial support and connections around a venture’s growth needs.

Historical programme experience

Case & evidence

What the healthcare evidence establishes

Implementation, pilot study, research collaboration and regulatory clearance are reported separately. The available record does not establish a verified aggregate of paid international customers. That question needs company-level contract or revenue evidence.

Named hospital evidence International customer evidence

NEXT STEPS

First step: commission the eight-week Sprint

We propose that A*STAR commissions the eight-week Sprint first. The immediate next step is a joint scoping call with A*STAR, Enterprise Singapore and Brinc to agree the Sprint brief, followed by a Singapore working session to finalise mobilisation. The longer programme is considered after the Sprint findings are reviewed.

  1. 01

    Agree and commission the Sprint

    Confirm the eight-week brief, agency roles, procurement and signatory, start date and acceptance criteria.

  2. 02

    Mobilise the validation work

    Provide a representative pipeline, agree confidentiality and referral criteria, and confirm named owners and delivery capacity.

  3. 03

    Review the findings at week eight

    Assess the prioritised pipeline, validation findings, delivery plan and resource recommendations. Decide whether to proceed, refine or pause; approve the 24-month pilot separately if warranted.

Working-session agenda

QUESTIONS & ANSWERS

What the agencies need to know

Answers on programme fit, outcomes, delivery and evidence. They describe the proposed operating model for review and confirmation.

22 questions

What are we being asked to commission now?

The immediate proposal is an eight-week Design and Portfolio Validation Sprint commissioned by A*STAR. It produces the portfolio evidence and delivery plan needed to decide on the 24-month pilot. The pilot and any international recruitment workstream require separate commissioning decisions.

Supporting detail ↗
What do we receive if the Sprint recommends pausing?

The agencies retain a prioritised project register, validation findings, initial venture hypotheses, customer and partner pathways, and staffing and capacity recommendations. The report records why opportunities should proceed, change or pause. Those outputs have value even if the pilot is not commissioned.

Supporting detail ↗
How does this complement existing Singapore venture support?

The Sprint maps existing support and project ownership before the delivery plan is finalised. Each venture plan identifies the work still needed, who will lead it and the handoffs to existing teams or programmes. Brinc’s proposed contribution is practical market validation, venture planning, entrepreneurial leadership, customer pathways and capital readiness.

Supporting detail ↗
Can ventures from outside A*STAR take part?

Yes. The proposed intake includes eligible Singapore ventures referred through Enterprise Singapore and the wider local ecosystem, alongside A*STAR projects and ventures. All referrals use common eligibility and readiness criteria. Entry and the level of support depend on fit, evidence and available capacity.

Supporting detail ↗
What happens to an existing company that does not need formation support?

It can enter the growth track after assessment. Work can focus on customer development, adoption or pilot preparation, commercial priorities and capital readiness. A venture moving from formation to growth remains one venture in the programme register.

Supporting detail ↗
How does the proposed capacity support the spin-off targets?

The Sprint tests the pipeline, readiness, staffing and timetable against the targets. Up to 15 formation assessments a year, 8–10 validated theses across the pilot and 6–8 growth ventures supported concurrently measure different work. They are not additive or guaranteed conversion rates. The additional ten spin-offs by August 2030 require continued formation activity and separately agreed resources after the pilot.

Supporting detail ↗
Must each of the ten spin-offs meet all three financial thresholds?

No. Each must meet at least one threshold by August 2030: S$1 million sales revenue OR S$10 million investment OR S$50 million post-money valuation. A company meeting more than one threshold still counts once. The Sprint establishes measurement periods, eligibility, attribution and evidence requirements.

Supporting detail ↗
How will progress be verified?

One project and venture register will record source, baseline, track, owner and evidence. Reports distinguish introductions, meetings, expressions of interest, letters of intent, signed pilots, completed pilots and paid customer contracts. Revenue, investment and valuation require agreed entity, period and verification rules. Valuation must relate to evidenced financing or another agreed event.

Supporting detail ↗
Can the programme still meet the August 2030 ambitions?

That must be tested against the actual start date and pipeline. The pilot runs for 24 months from an agreed start following the Sprint and separate approval. The Sprint will assess the remaining time to August 2030 and the resources required. Any continuation is a further decision; a full additional two years is not automatic.

Supporting detail ↗
Who will deliver the work in Singapore?

The proposed model combines local leadership and portfolio management with regional contributors and venture-specific specialists. The two Singapore roles under recruitment are distinct from the named regional contributors based in Hong Kong, Dubai and Abu Dhabi. Named assignments, dedicated time, interim cover and specialist coverage must be agreed before mobilisation. Recruitment remains in progress; the two roles do not replace separately assigned clinical, regulatory and IP expertise.

Supporting detail ↗
What is Enterprise Singapore’s proposed role?

Enterprise Singapore is the proposed co-organiser and community and ecosystem lead, supporting eligible-company referrals, network mobilisation and relevant enterprise pathways. The agencies will confirm the liaison, decision rights and contributions. The proposal does not assume an agreed funding split.

Supporting detail ↗
What happens if a project is not ready or the pipeline is too weak?

A gate review can refine, hold or stop work, recording the evidence and what is needed for reconsideration. The same standards apply to wider ecosystem referrals. The programme can revisit sourcing and the balance of formation and growth work. Material changes to capacity, timing or resources require agreement before additional commitments are made.

Supporting detail ↗
How are deliverables accepted?

Each deliverable has a named reviewer, approving authority and agreed review event. The record distinguishes accepted outputs, requested revisions and withheld items. Brinc prepares the work and evidence; scientific and IP owners decide matters within their remit; the commissioning authority accepts contracted services and separately authorises the next phase.

Supporting detail ↗
What is included, and what requires separate agreement?

The core proposal covers agreed assessment, validation, venture-building support, founder and partner engagement, reporting and community coordination. Investment capital, venture operating costs, founder or EIR salaries, clinical trials, regulatory submissions, medical services, legal and IP-transfer work, third-party specialist fees, major events and travel are outside the core scope unless expressly added. Commercial terms are agreed separately.

Supporting detail ↗
Who controls IP and confidential information?

Background IP remains with its existing owner and institutional scientific and IP authority is retained. Before mobilisation, the parties agree the treatment of programme outputs, authorised access, confidentiality, data ownership and stewardship, retention, return or deletion, and publication permissions. Programme participation does not itself grant an IP licence or access to confidential research.

Supporting detail ↗
Who makes clinical and regulatory decisions?

The programme identifies clinical and regulatory dependencies and incorporates them into venture plans with appropriate experts. Relevant institutional owners and qualified specialists retain responsibility within their remit. Clinical trials, regulatory submissions and medical services require separate scope; introductions do not guarantee hospital procurement or regulatory approval.

Supporting detail ↗
What experience is most relevant to this programme?

Singapore experience includes research-origin venture examples including MyrLabs, AuroraFood and Botsync, the historical NHIC collaboration and Future Health Asia cohort activity. Dated Incheon BioMedTech and university programme records add founder preparation, ecosystem visits and mentoring; TeX-Corps records add healthcare and research matching. Collaborators retain attribution. These records describe activity, not confirmed attendance, completed pilots or paid outcomes. CityUHK and startAD provide further operating examples.

Supporting detail ↗
Are international customers or hospital opportunities guaranteed?

No. Brinc helps ventures identify relevant counterparties and prepare for a buying, adoption or pilot decision. Engagement depends on readiness, counterparty priorities and approvals. The current portfolio evidence does not establish a complete verified count of paid international customers. Pilots, hospital activity and paid sales will be reported separately.

Supporting detail ↗
Do community members receive intensive venture support or investment?

Community participation provides learning, relationships and referrals. Intensive formation or growth support requires a selection decision and an agreed work plan. Membership does not confer investment, a funded place or access to confidential research. International startup recruitment is an optional workstream with its own commissioning, capacity and reporting.

Supporting detail ↗
What do the Singapore programme records demonstrate?

They record founder preparation, mentoring, pitch feedback, ecosystem visits and counterpart matching. Examples include Incheon BioMedTech in November 2025, Yonsei/Halla in January 2026, Pukyong-led immersion in February 2026 and TeX-Corps in October 2026. Each retains its recorded collaborators. The activity register does not distinguish scheduled, attended, completed or cancelled events, so it does not establish completed clinical pilots, paid sales or institutional commitments.

Supporting detail ↗
Are the historical contributors committed to this programme?

No. Allison Hui May Nam, Edmas Neo, Marc Palet, David Hwan and Dorothy Yuan are dated historical contributor examples, with affiliations recorded at the time. They are separate from Brinc staff and the delivery roles to be appointed. Any new involvement requires agreement on current affiliation, role, availability and allocated time.

Supporting detail ↗
Does the healthcare matching establish clinical or regulatory capacity?

No. TeX-Corps records list matching involving National Neuroscience Institute; the source grouping NTU / IMH / Centre for AI in Medicine; TÜV SÜD PSB; and ClinActis. Matching does not establish attendance, services purchased, clinical pilots or institutional commitments. Accountable clinical, regulatory and IP specialists must be assigned separately for the proposed programme.

Supporting detail ↗

FULL PROPOSAL

Full programme specifications

Explore the complete programme, biographies and supporting cases. Qualifications and public evidence sit beside each topic.

82 topics

Purpose and ambition

01A Singapore platform for Precision Health ventures

A*STAR and Enterprise Singapore

Proposed venture-building programme delivered by Brinc

November 2026

Context & qualifications

This proposal follows the November discussion. Its purpose is to agree how the agencies and Brinc can build a sufficient pipeline and support ventures through formation and growth.

02Build a stronger pipeline across Singapore

A*STAR contributes research assets and ventures

Enterprise Singapore mobilises eligible startups through its network

Brinc assesses the combined pipeline and prioritises work with venture teams

A shared community supports founders as their needs evolve

Context & qualifications

A wider Singapore intake addresses the challenge of generating sufficient venture volume from A*STAR alone, while maintaining common selection standards.

03A programme built around the agencies’ questions

Healthcare expertise and delivery capacity

Singapore relationships and research-origin ventures

Evidence of hospital activity and international reach

A clear operating scope and accountable team

Context & qualifications

Enterprise Singapore asked about healthcare expertise, Singapore capacity, hospital activity and international reach. The Singapore examples address those questions; the programme sections set out the work Brinc proposes to deliver.

04Brinc connects research, founders, customers and capital

Source and assess technologies and ventures

Test market demand and commercial pathways

Build founder capability and venture readiness

Support pilots, customer development and capital conversations

75+ programmes | 260+ portfolio companies

Context & qualifications

Brinc's experience covers opportunity assessment and practical venture support, with group credentials of 75+ programmes and 260+ portfolio companies. The dated examples below describe the work undertaken. Support for this programme will depend on venture readiness and the relevant institutional decisions.

14A*STAR's Precision Health focus areas

Physical health and age-related function, including sarcopenia

Brain health

Gut–organ axis

Socio-environmental factors

Preventive population health and healthy longevity

Context & qualifications

A*STAR confirmed these focus areas. The Sprint evaluates available projects across them and determines where credible venture opportunities and delivery resources align.

15Healthcare experience within the Brinc portfolio

Internal portfolio snapshot, 12 November 2026 | 25 of 197 active companies are Healthcare-tagged (12.7%, rounded)

The active-company subset differs from the cumulative 260+ portfolio credential

Overlapping sector tags; internal records, not founder-verified

Use the deep-dive to assess clinical, technical, commercial and delivery needs

Context & qualifications

The active-company extract contains 197 unique companies, of which 25 carry a Healthcare tag. Categories overlap and are internal records rather than founder-verified classifications. The wider historical healthcare cases illustrate different pathways and are not all members of that active subset. The credentials deep-dive informs the Sprint’s review of the actual candidate portfolio.

16One platform supports two core venture tracks

Track One | Form new ventures in Singapore

Track Two | Grow existing A*STAR and Enterprise Singapore network ventures

Shared intake, specialists, community, governance and reporting

Optional international startup recruitment

Context & qualifications

Existing ventures can enter the growth track after assessment. New ventures can progress into growth support when ready. The optional recruitment workstream has its own scope and capacity.

17Start with an eight-week Sprint, then a 24-month pilot

A*STAR commissions the eight-week Design and Portfolio Validation Sprint

A separately approved 24-month pilot follows the Sprint decision

Quarterly reviews to adjust portfolio priorities

Review any extension against the August 2030 ambition

Context & qualifications

The eight-week Sprint and the 24-month pilot are separate phases. A*STAR commissions the Sprint; the pilot requires a separate decision after review of the Sprint findings. Before work starts, the parties will confirm the timetable and its relationship to the fixed August 2030 ambitions. Any extension requires a further decision.

18A*STAR's ambitions for venture creation and growth

Build a pipeline of 20–30 potential spin-off projects

Create at least five spin-offs during the pilot

Create another ten spin-offs by August 2030

Ten spin-offs to meet a global-investibility threshold by August 2030

Context & qualifications

These are the client’s written ambitions. The Sprint tests pipeline volume, resourcing and timing. Performance reporting will track both Brinc’s service outputs and progress towards shared venture outcomes. These are shared ambitions, dependent on scientific quality, founders, IP decisions, market demand and capital availability. Brinc is accountable for agreed service outputs, evidence quality, qualified introductions and delivery cadence; it does not guarantee capital raised, regulatory approval, clinical outcomes, procurement decisions or company valuations.

19Three alternative financial thresholds

S$1 million sales revenue

OR S$10 million investment

OR S$50 million post-money valuation

Agree the measurement date, which entity is measured and the supporting evidence

Context & qualifications

The Singapore-dollar thresholds are alternatives. Before reporting progress, the parties should agree which entity is measured, the measurement date and how results will be verified. Revenue and investment also need an agreed reporting period and currency basis. Valuation must be supported by a financing event or another agreed basis.

Programme design

23Sprint weeks 1–4: establish the pipeline and delivery baseline

Weeks One–Two | Align outcomes, owners, access and definitions

Weeks Three–Four | Review pipeline and referrals, interview teams and assess readiness

Record critical gaps in IP, founders, technology and market demand

Produce the prioritised opportunity register, existing-provider map and documented pipeline/staffing baseline

Context & qualifications

The first half creates a shared view of the pipeline and each opportunity’s needs. It also maps existing venture-support providers and records the available staffing baseline. A*STAR projects and Enterprise Singapore referrals use common criteria, authorised information access and appropriate confidentiality arrangements.

24Sprint weeks 5–8: test opportunities and agree the operating plan

Weeks Five–Six | Test use cases, customer pathways and specialist needs

Weeks Seven–Eight | Agree portfolio mix, capacity, gates and reporting

Set the community calendar and pilot roadmap

Decide whether to commission international recruitment

Context & qualifications

The second half of the Sprint prepares the decision on delivery. The plan identifies the selected portfolio, scope, dependencies and resources needed to start.

25The Sprint decision package

Prioritised portfolio with track assignments and evidence gaps

Venture hypotheses and initial validation findings

Delivery plan, roles, capacity and governance

Milestone roadmap and proceed, refine, expand or pause recommendations

Context & qualifications

The decision package needs traceable evidence and a usable operating plan that identifies unresolved inputs. Reviewers and the authority to accept each output will be named before mobilisation. The review will record accepted outputs, requested revisions and items not accepted. Approval of the pilot is a separate decision; outputs are not accepted automatically after a period of time.

26Track One: form new ventures in Singapore

Assess research assets and market problems

Interview users, buyers and potential partners

Develop the venture thesis and business-model options

Match founders and operators

Prepare IP, formation and launch milestones

Context & qualifications

A technically promising project may need a different market application, a new operator or more research before formation. The process allows the parties to pause or reshape projects when the evidence calls for it.

27What a venture formation pack contains

Customer problem and differentiated proposition

Technology evidence and IP pathway

Founder capability, gaps and incentives

Product, validation and capital milestones

Recommendation and accountable next steps

Context & qualifications

Each selected project produces a concise decision document. The institution retains authority over its IP and scientific resources, with Brinc preparing the commercial and formation work.

28Track Two: help existing ventures reach customers and capital

Diagnose product, customer and funding readiness

Build a focused customer and pilot pipeline

Shape pilot scope and commercial success criteria

Prepare data rooms and investor narratives

Support selected market-entry pathways

Context & qualifications

Support is tailored to each venture’s starting position. Brinc coordinates work around the next meaningful milestone and records the evidence gained from customer and investor engagement.

29Pilot preparation starts with a buying or adoption decision

Identify the user, buyer, payer and clinical sponsor

Agree objectives, responsibilities and baseline

Confirm evidence, integration and regulatory dependencies

Define success criteria and the next commercial decision

Context & qualifications

A good pilot has an owner and a decision at its conclusion. Clinical, regulatory and procurement responsibilities remain with the appropriate institutions and specialists.

30Optional recruitment of international startups

Source companies with a credible reason to establish operations in Singapore

Assess technical quality, founder commitment and readiness to enter Singapore

Connect selected teams to research and ecosystem counterparts

Prepare a local operating plan and track progress towards establishment

Context & qualifications

This workstream is separately commissioned. Selection should serve the programme’s priorities and local ecosystem. Incorporation, local operations and relocation are measured only when evidenced.

31HOURS Technology: an introduction to A*STAR

Brinc introduced HOURS Technology to Radiana Soh

An A*STAR discussion took place in October 2026

Follow-up explored scientific collaboration opportunities

The optional track would formalise sourcing, screening and follow-through

Context & qualifications

HOURS provides a practical example of identifying a company and connecting it to the appropriate research team. Its materials and chemistry focus illustrates the process that can be adapted to suitable Precision Health candidates.

32Review points for venture progression

Eligibility and assessment

Deeper validation

Formation or intensive growth support

Launch or pilot progression

Scale readiness and continuation

Context & qualifications

Brinc prepares each evidence pack and recommendation. The relevant institutional owner and Brinc jointly approve admission into committed delivery capacity within delegated authority. Institutions retain their scientific and IP decisions. Any progression against Brinc’s recommendation records the exception, resource impact and outcome attribution before additional work. Hold or stop decisions state the evidence needed for reconsideration.

33A shared community supports venture milestones

Monthly founder or specialist sessions

Regular mentor office hours

Quarterly commercial or investor roundtables

Annual portfolio showcase, within agreed resources

Follow-up measured against venture needs

Historical Singapore methods | Founder preparation, mentoring and targeted matching

Context & qualifications

This is the working community cadence for agency review. Enterprise Singapore leads ecosystem mobilisation; Brinc curates sessions, prepares introductions and follows through. Routine coordination is in the service model; major event production, venues and separately commissioned costs require additional scope and resources. Community membership does not automatically confer funded venture-building support, programme selection, investment or access to confidential research. Dated Singapore records illustrate founder preparation, mentoring, pitch feedback and targeted matching. The proposed community applies these methods through a venture-needs register, a named owner for each next action and separately agreed participant roles.

39The proposed 24-month pilot sequence

Months One–Three | Mobilise, screen and validate priorities

Months Four–Six | Develop formation and growth plans

Months Seven–Twelve | Progress ventures and review results

Months Thirteen–Twenty-Four | Apply lessons, deepen support and prepare ventures for growth

Context & qualifications

The Sprint will refine this proposed sequence. Existing ventures may be ready to progress earlier; projects originating in research will move forward as their evidence and teams develop.

Delivery and governance

20Who delivers, decides and reviews

Research and scientific access | A*STAR leads; Brinc assesses commercial pathways; Enterprise Singapore connects complementary ventures

Startup recruitment and community | Enterprise Singapore leads mobilisation; Brinc defines criteria, screens and runs the programme; A*STAR refers eligible ventures

Venture building and growth | Brinc leads delivery, specialist coordination and follow-through; both agencies provide relevant access and decisions

IP and institutional approvals | A*STAR or the relevant asset owner decides; Brinc prepares commercial recommendations

Stage gates and reporting | Brinc prepares evidence and recommendations; the agreed joint governance group reviews progression

Commissioning and resources | A*STAR commissions the Sprint; agency owners resolve procurement, signatory, start date and inter-agency funding; Brinc defines delivery work packages and capacity

Context & qualifications

Brinc undertakes day-to-day delivery and provides evidence for review at each gate. A*STAR commissions the Sprint. Procurement details and institutional contributions remain to be recorded, and the 24-month pilot is separately approved. Enterprise Singapore’s co-organiser and ecosystem role is the working proposal for agency confirmation.

21What Brinc will produce

Screening records and prioritised venture register

Venture theses and customer-discovery evidence

Founder plans and formation-readiness packs

Pilot briefs, customer plans and investor-readiness materials

Monthly dashboard and quarterly decision packs

Context & qualifications

Each workstream produces reviewable outputs linked to a decision. Working capacity is up to fifteen formation assessments per year, eight to ten validated theses across the pilot and six to eight active growth ventures at a time. These are different measures, not additive cohort commitments, and remain subject to Sprint validation of workload, budget and staffing.

22Enterprise Singapore leads a wider Singapore intake

Recruit eligible companies through the Singapore network

Bring universities, other institutes of higher learning and healthcare groups into relevant sourcing

Connect growth ventures to enterprise and market-development pathways

Co-design a community calendar around portfolio needs

Context & qualifications

The wider intake helps address pipeline volume while serving eligible Singapore ventures. Referral criteria, data access and responsibility for each source would be agreed with Enterprise Singapore.

38Programme governance and decision-making

Fortnightly working group for delivery and dependencies

Quarterly steering review for scope, capacity and outcomes

Named institutional owners for scientific and IP decisions

One decision log, risk register and accountable owner per action

Context & qualifications

The working group resolves delivery matters and escalates material decisions. The steering group reviews progress and approves changes to scope and resources through the agreed process.

40What the programme will report

Unique projects, referral sources and track distribution

Validated theses, stage gates and founder readiness

Introductions, pilots and customer milestones

Capital readiness and evidenced investment events

Capacity, dependencies and progress against client ambitions

Context & qualifications

Count each project once and record transitions between tracks. Report introductions, meetings, pilots and contracts as distinct milestones. The optional inbound track has a separate set of measures.

67How programme outputs will be reviewed and accepted

Sprint | Evidence-backed portfolio and executable operating plan

Formation | Venture thesis, founder plan and milestone recommendation

Growth | Commercial diagnostic, pilot or customer plan and next decision

Reporting | Traceable data, progress and open decisions

Context & qualifications

Brinc prepares the agreed outputs and evidence. The working group reviews completeness; scientific and IP owners decide within their remit; the commissioning authority accepts contracted services and separately approves later phases. Before mobilisation, agree the reviewers, accepting authority and review process. Each review will record its date, decisions, requested revisions and unresolved inputs. Outputs are not accepted automatically, and venture outcomes are not guaranteed.

68Criteria for selection and progression

Mandate and focus-area fit

Technology evidence, IP and founder commitment

Customer need and adoption pathway

Capital intensity and regulatory dependencies

Capacity, scalability and readiness for the next step

Context & qualifications

The Sprint determines weights and critical conditions. A total score supports comparison, while unresolved IP, safety, ownership or delivery issues can require a hold before further work.

69Scope and resources to confirm before work starts

Institutional project access and nominated owners

Defined IP, clinical, regulatory and procurement responsibilities

Agreed delivery capacity and specialist resources

Separate scope for venture funding, trials, legal work and major events

Written approval for material changes

Context & qualifications

The planning baseline is up to fifteen formation assessments per year, eight to ten validated theses across the pilot and six to eight active growth ventures at a time. These are distinct workload measures, subject to A*STAR confirmation and Sprint validation, not guaranteed conversions or spare capacity for optional recruitment. Record input owners and authority for additional work. Scope changes require written resource and timetable assessment before implementation. Excluded unless expressly added: investment capital; venture operating costs; founder or entrepreneur-in-residence salaries; clinical trials, regulatory submissions and medical services; IP transfer and legal work; specialist third-party fees; major event production, venues and sponsorship; travel; guaranteed customer contracts; and financial returns. Brinc may coordinate specialists while professional responsibilities remain with the relevant advisers and institutions.

70Consistent records and evidence of progress

One identifier per venture or project

Track transitions recorded against the same identifier

Introductions, letters of intent, signed pilots and paid contracts recorded separately

Company outcomes supported by dated evidence

Inbound candidates reported against their own landing milestones

Context & qualifications

Agree project identifiers, reporting periods, outcome attribution, data stewardship, ownership of programme outputs, authorised access, retention and return or deletion arrangements before mobilisation. Background IP and institutional scientific decisions remain with their owners. Report track transitions without double counting and keep optional inbound milestones separate. The parties agree reporting and publication permissions and permitted use of confidential project information. Venture participation requires founder engagement and permission to use project information. Access is limited to authorised users and purposes.

79Delivery risks, proposed actions and owners

Risk | Mitigation | Working owner

Pipeline volume or quality | Broaden eligible Singapore referrals; apply common screening; reforecast at reviews | Steering group

Mobilisation and timetable | Agree an executable start; reconcile pilot delivery with August 2030 ambitions | A*STAR and Brinc

Local delivery capacity | Confirm responsibilities and allocation; complete recruitment and interim cover | Brinc

Specialist gaps | Define clinical, regulatory, legal and IP input for each venture | Brinc and institutional owners

IP and approval timing | Identify authorised owners early; include an IP pathway in each formation plan | Relevant institution or asset owner

Unclear or double-counted outcomes | Use shared definitions, identifiers and dated evidence | Working group

Scope growth without resources | Assess workload, cost and timetable before written approval | Steering group

Confidential information | Use authorised access, agreed purposes and controlled external disclosure | All parties

Context & qualifications

The risk register is maintained as part of delivery rather than treated as a one-off proposal checklist. The working group tracks actions and dependencies, and escalates material scope, resource or timetable decisions to the steering group. Institutional decisions remain with the authorised owner. The same evidence model supports both reporting and early intervention.

Team and talent

34Local programme ownership with regional and specialist support

Director, Singapore | Programme leadership and stakeholder alignment

Innovation Manager | Day-to-day delivery and portfolio coordination

Healthcare specialists | Clinical, regulatory and technical expertise

Brinc regional platform | Customer, investor and market support

Context & qualifications

The working operating model combines local ownership with regional support. Guillermo provides executive sponsorship, Edwin APAC oversight, Tom cross-border partnerships, Levi regional programme methods, Olga contracting support, Nick founder validation and Leonardo innovation and venture-screening support. Director, Singapore and Innovation Manager are the proposed local delivery roles under recruitment; the named regional contributors are shown separately. Dedicated allocation and specialist assignments are recorded before mobilisation.

74Executive sponsorship and APAC delivery oversight

Guillermo Ginesta | Executive sponsor | Hong Kong

Leads Hong Kong and Greater Bay Area strategy, startup selection and founder support.

Earlier INFINITI LAB work covered startup diligence, programme expansion and corporate innovation.

MSc Marketing & Strategy, University of Warwick.

Programme contribution | Strategic direction, stakeholder alignment and escalation.

Edwin Lee | APAC delivery oversight | Hong Kong

Accelerator operations experience at Brinc.

Earlier institutional sales analysis at Ned Davis Research and fixed-income trade operations at State Street Global Advisors.

BSc Business Administration, Babson College.

Programme contribution | Delivery oversight, operating discipline and review cadence.

Working team proposal; programme allocation follows the agreed delivery plan.

Context & qualifications

Guillermo brings experience connecting corporate priorities, startup selection and founder support. Edwin brings accelerator operations and financial-services experience. Their roles provide senior direction and delivery oversight for the proposed platform, alongside the local programme team. The operating plan assigns responsibilities and time against the selected portfolio.

75Partnership development and founder validation

Tom Purdon | Head of Cross-Border | Dubai

Experience in startup scouting, selection, programme operations and investor relationships.

Previous MBRIF work included mentor, investor and partner connections.

Earlier project-analysis and client-services roles at Amazon and L’Oréal.

Programme contribution | Partnership pathways, ecosystem connections and international market support.

Nick Ramil | Founder validation support | Hong Kong

Brinc founding-team and validation experience supporting founders from product concept to launch.

Experience in product-launch strategy, distribution engagement and entrepreneur coaching.

Earlier market-entry and business-development work across Hong Kong and mainland China.

Programme contribution | Customer discovery, proposition testing and founder readiness.

Working team proposal; specialist assignments and dedicated time follow portfolio needs.

Context & qualifications

Tom's experience covers programme operations and work with partners and investors. Nick has helped founders develop, launch and grow products, including distribution and market entry. Their proposed contribution supports commercial work for Singapore ventures. Any market engagement depends on the venture's needs and the counterparty's interest.

76Regional programme design and innovation delivery

Levi Lewandowski | Head of UAE | Abu Dhabi

Leads government and corporate innovation programme design and delivery.

Experience translating innovation priorities into project plans, startup selection, stakeholder coordination and technology-pilot activity.

Earlier accelerator operations at EC Accelerate and commercial-strategy rotations at Boeing.

Programme contribution | Mobilisation, workstream design and pilot-execution methods.

Leonardo Peralta Tapia | Innovation Manager | Abu Dhabi

Runs founder programmes spanning outreach, venture screening, workshops, mentoring and investor preparation.

Prior digital-health work at Vitalls covered pricing, commercial-model options and investor positioning.

Earlier venture-screening experience at Siemens Energy Ventures; BSc Aerospace Engineering, TU Delft.

Programme contribution | Research, screening, commercial analysis and programme coordination.

Regional support complements the Singapore team; it is not counted as Singapore-based staffing.

Context & qualifications

Levi brings programme design and pilot-delivery experience, including preparation of delivery plans. Leonardo combines technical training, venture screening and founder programmes with previous digital-health commercial strategy work. They can support agreed work packages while local staff retain day-to-day responsibility for Singapore delivery.

77Contracting support and Singapore delivery coverage

Olga Dontsova | General Counsel | Hong Kong

Hong Kong solicitor and New York attorney.

General-counsel experience at Brinc and OpenPort, with earlier law-firm practice.

Experience spans commercial and employment matters, governance and company structuring.

Programme contribution | Programme contracting and coordination of legal workstreams.

Singapore delivery coverage

Director, Singapore and Innovation Manager remain under recruitment. Appointments, availability and dedicated time must be confirmed before mobilisation.

The delivery plan assigns local responsibility, specialist input and regional support to each workstream.

Institutional owners retain their scientific, IP, procurement and clinical decision rights.

Programme support roles are distinct from appointed hires and institutional authority.

Context & qualifications

Olga provides programme-contracting experience; the relevant institutions and qualified advisers retain their own legal and approval responsibilities. Director, Singapore and Innovation Manager remain under recruitment. Appointments, availability and dedicated time must be confirmed before mobilisation. Named regional contributors and venture-specific specialists support the proposed delivery roles. Brinc has an active Singapore network through its portfolio companies, investor relationships and mentors, alongside an established record of venture support and ecosystem activity. Programme participation is separately agreed.

44Specialist expertise required for each venture

Clinical use and adoption | Practitioners and health-system innovators

Product and evidence | Technical and regulatory specialists

Company formation | Founders, operators and IP advisers

Commercial growth | Buyers, partners and investors

Context & qualifications

Working coverage combines named regional experience, local delivery roles and venture-specific specialists. Formation needs IP and founder support; growth needs customer and capital-readiness work; community and reporting need local coordination. The accountable healthcare, regulatory and IP specialists and their allocated time must be documented for mobilisation. Historical Singapore contributors and matching examples are distinct from a confirmed specialist roster.

10Specialist healthcare experience can be matched to venture needs

Bipin Bhola previously served as Brinc’s MedTech technical head

His experience spans clinician innovation and venture development

Duke-NUS describes his work in its Health Innovator Programme

Current public profile | Assistant Professor, Duke-NUS Office of Innovation and Entrepreneurship; COO, Kaleidoscope Therapy Group

Context & qualifications

Bipin’s historical Brinc MedTech role and current public professional biography illustrate relevant specialist experience. Any contribution to the proposed programme would be separately agreed for the selected venture needs. His current institutional affiliations do not establish programme partnerships or allocated time. Historical Singapore contributors and counterpart matching provide further examples of relevant ecosystem engagement. They do not replace accountable clinical, regulatory and IP specialist assignments and allocated time.

35Two Singapore roles under recruitment

Director, Singapore | Programme leadership and accountable local delivery

Innovation Manager | Venture support and programme operations

These are two distinct Singapore delivery roles, separate from the seven regional contributors

Appointments, eligibility, availability and dedicated time require confirmation before mobilisation

Context & qualifications

Director, Singapore and Innovation Manager remain under recruitment. Appointments, availability and dedicated time must be confirmed before mobilisation. The proposed delivery model combines these two roles with the named regional contributors. The operating plan must record named responsibilities, reporting lines, time allocation, start dates and interim cover.

36Director, Singapore: programme leadership requirements

Lead local programme delivery and agency coordination

Oversee opportunity assessment, venture formation and growth priorities

Connect healthcare commercialisation needs with appropriate specialist support

Own portfolio reviews, delivery quality and escalation

Role under recruitment; appointment and allocated time remain to be confirmed

Context & qualifications

The Director role requires complementary experience in venture development, programme leadership and Singapore ecosystem engagement. The selected delivery model must cover both the formation and growth tracks. Clinical, regulatory and institutional decisions remain with the appropriate qualified and authorised owners.

37Innovation Manager: delivery and venture-support requirements

Coordinate venture work plans, milestones and founder support

Maintain intake, evidence and reporting records

Prepare relevant ecosystem introductions and track follow-through

Coordinate research translation, formation and pilot-preparation workstreams

Role under recruitment; appointment and allocated time remain to be confirmed

Context & qualifications

The Innovation Manager supports day-to-day execution alongside the Director and institutional project owners. The two roles need complementary capabilities and sufficient allocated capacity. Programme coordination does not transfer clinical, regulatory, legal or IP authority to the delivery team.

72Singapore leadership: capability and mobilisation requirements

Healthcare commercialisation and venture-building experience

Programme governance, portfolio prioritisation and agency coordination

Founder development, partner engagement and commercial readiness

Confirmed responsibilities, availability and dedicated time

Specialist support matched to portfolio needs

Context & qualifications

Before mobilisation, Brinc will confirm accountable local leadership, allocation, start dates and interim cover. The final role combination must support the selected portfolio and proposed capacity. Relevant experience does not by itself establish institutional access or a counterparty commitment; any contribution must be agreed separately.

73Singapore delivery: capability and specialist coverage

Founder support and research-commercialisation coordination

Customer discovery, adoption questions and pilot preparation

Evidence management, community follow-through and performance reporting

Named clinical, regulatory, legal and IP specialists where needed

Agreed reporting lines, capacity and absence cover

Context & qualifications

Local delivery roles and specialist assignments are separate requirements. The operating plan must identify accountable people, their responsibilities and allocated time. Two recruited roles do not automatically provide every clinical, regulatory or IP speciality. Institutions and qualified specialists retain decisions within their remit.

Singapore credentials

42Supporting credentials and delivery detail

Singapore relationships and specialist evidence

Healthcare and hospital examples

Hong Kong delivery and market-access cases

MENA programme and commercialisation cases

Operating definitions and deliverables

Context & qualifications

This reference section groups the credentials and delivery detail by topic. Each example describes the documented activity and its relevance to the proposed Singapore programme.

43How the Singapore experience relates to the proposed work

Research-origin pathway | MyrLabs, AuroraFood and Vigti

Research and founder engagement | NUS knowledge exchange and referrals

Historical MedTech programme | Future Health Asia collaboration

Specialist and institutional history | Bipin’s Brinc MedTech experience and the March 2023 NHIC MoU

Adoption evidence | SmartPeep’s named hospital activity

Local programme activity | Incheon BioMedTech, university preparation and TeX-Corps matching, 2025–26

Context & qualifications

The examples cover complementary parts of the proposed programme. Re-engagement starts from the selected portfolio’s needs and is agreed with each counterpart.

05Singapore experience in research commercialisation and venture support

Research-origin examples include MyrLabs, AuroraFood, Vigti and Botsync

NUS relationships have supported research exchange and founder referrals

The Future Health Asia collaboration provides MedTech programme experience

Specialist experience includes Bipin Bhola’s past Brinc MedTech role

Singapore programme methods and historical contributors | Dated records, 2024–26

Context & qualifications

These examples demonstrate complementary Singapore pathways. Dated programme records add founder preparation, mentoring, pitch judging, ecosystem visits and targeted matching. Re-engagement is agreed around venture needs; historical activity does not establish current institutional commitments.

06MyrLabs: supporting an A*STAR research-origin venture

Origin in A*STAR’s Singapore Institute of Manufacturing Technology

Brinc accelerator and advisory relationship documented in 2020

Participation in a Brinc-operated HKSTP landing cohort

Relevant experience in supporting a research-origin company across markets

Context & qualifications

MyrLabs is a robotics company. This case shows Brinc's experience supporting a venture that originated in research and exploring opportunities in other markets. Support for a future programme venture would depend on its technology and commercial readiness.

07University spin-offs: different needs at each stage

AuroraFood | NUS food science spin-off and functional-food proposition; included in Brinc’s 2020 Hong Kong programme and investment portfolio

Vigti | NTU spin-off with early backing from Brinc and Artesian

Botsync | NTU-linked robotics venture in Brinc’s portfolio

Support needs span IP, founders, market validation and customer access

Context & qualifications

AuroraFood is relevant to nutrition; Vigti and Botsync provide research-commercialisation examples from other sectors. Each has different support needs. Precision Health ventures would also need the appropriate sector specialists.

08NUS: research exchange and founder referrals

NUS delivered an IP and research collaboration session to Brinc companies in 2020

NUS GRIP circulated a Brinc accelerator call in 2024

Further discussions explored introductions to GRIP ventures

A potential route to revisit for eligible Singapore opportunities

Context & qualifications

The historical relationship includes actual knowledge exchange and referral activity. The current National GRIP structure can be approached through the relevant relationship owners when the programme’s eligibility and intake needs are agreed.

09Future Health Asia: the 2021 Singapore–Hong Kong MedTech programme

Cross-border MedTech accelerator announced in January 2021

Spring cohort included CAREFUL, Altris AI, SAMA and Healium Digital

Programme combined specialist input with venture development

Relevant experience for designing a focused healthcare cohort

Context & qualifications

The partner announcement and Demo Day record establish the programme and cohort. For this proposal, the lesson is how to combine specialist healthcare support with founder development and investor preparation.

78NHIC: the March 2023 collaboration framework

NHIC and Brinc | Historical collaboration framework

March 2023

Brinc and NHIC executed a three-year memorandum of understanding.

Collaboration scope

Explore support for healthcare and biomedical projects through knowledge sharing, open innovation and talent development.

Talent-development pathway

The agreement’s annex included collaboration relating to the Innovation and Enterprise Fellowship.

Relevance to Precision Health

Experience structuring collaboration around healthcare innovation, research translation and talent development.

Historical agreement; any renewed participation or programme commitment is separately agreed.

Context & qualifications

The memorandum establishes a historical institutional relationship and a framework for exploring healthcare and biomedical innovation support. Its scope included knowledge sharing, open innovation and talent development. It does not by itself establish delivery outcomes, current participation in this proposal or a renewed signed agreement. The proposed programme would agree any new involvement with the relevant institutional owners.

80Singapore programme records show local delivery methods

Incheon BioMedTech | 3–4 November 2025

Five startups; demo activity, one-to-one matching and host visits. A CHI / Tan Tock Seng Hospital clinical ecosystem visit is recorded within the programme window.

Listed collaborators | Incheon, Tap Angel, Alysium and Brinc Korea

Yonsei / Halla KR-SG Pitch Challenge | 13–15 January 2026

Pitch training, judges and Block71 / Tenity sessions.

Listed collaborators | Idea Partners, Alysium and Brinc Korea

Pukyong-led university immersion | 3–5 February 2026

Mentoring, SMU / Block71 tours, faculty exchange and pitch activity.

Listed collaborators | Seed Partners, Alysium and Brinc Korea

Programme application | Prepare founders, match venture questions to appropriate counterparts and document follow-through.

These are dated activity records, not evidence of clinical or commercial outcomes.

Context & qualifications

The programme records do not distinguish scheduled, attended, completed or cancelled activity. They do not establish hospital adoption, completed clinical pilots, paid outcomes or future institutional participation. The CHI / Tan Tock Seng Hospital visit is dated to the 3–4 November programme window, not a verified exact day. Each new engagement would be agreed around a defined venture need.

81Historical Singapore collaborators and contributors

Allison Hui May Nam | Alysium / Nandina REM

Co-programme development and delivery, 2024–26.

Edmas Neo | Accrete Innovation

Lecture, mentoring and judging, March 2024.

Marc Palet | Vectr (2024); OMVC (2025–26)

Judging / mentorship in 2024; sessions and matching in 2025; judging in 2026.

David Hwan | Kadan Capital

Repeated judging records, January, February and October 2026.

Dorothy Yuan | Protégé

Judging records, January–February 2026.

Historical roles and affiliations as recorded. Future involvement and allocated time require agreement.

Context & qualifications

These contributors are historical activity examples, separate from proposed staff and specialist appointments. Edmas’s March 2024 programme entry lists Gwangju CCEI, Next Stage and Alysium without explicitly naming Brinc; it is not attributed as an exclusively Brinc-delivered engagement. Marc’s affiliation changes between the dated records. Repeated appearances do not represent additional people or committed capacity. Current affiliation, interest, responsibilities and time would be confirmed for any future role. These examples do not establish Singapore staffing or guaranteed access to their organisations.

82Healthcare and research counterpart matching

TeX-Corps | 26–30 October 2026

Recorded seven-startup programme with corporate / clinical matching and a demo.

Listed collaborators | Alysium, Brinc Korea and a Seed Partners contact

National Neuroscience Institute | 27 October 2026

Neuroscience counterpart matching.

NTU / IMH / Centre for AI in Medicine | 27 October 2026

AI-in-medicine counterpart matching.

TÜV SÜD PSB | 28 October 2026

Specialist counterpart matching.

ClinActis | 28 October 2026

Clinical-research counterpart matching.

Programme application | Match a venture’s question to an appropriate specialist conversation.

Matching entries do not establish completed pilots, paid services or future institutional commitments.

Context & qualifications

These dated matching records do not establish attendance, purchased services, paid sales, institutional endorsement or a committed clinical advisory panel. The seven-startup figure is the recorded programme cohort, not seven healthcare companies or seven completed outcomes. NTU / IMH / Centre for AI in Medicine retains the source grouping rather than establishing a single legal entity or new institutional relationship. The proposed programme would separately agree each contribution, responsibilities and time, and record the next evidence milestone.

11SmartPeep: documented hospital activity in Singapore and Malaysia

SmartPeep monitoring was implemented at Parkway East Hospital in Singapore in 2023

A published study evaluated SmartPeep in a Malaysian acute stroke unit

SmartPeep participated in Zeroth’s accelerator

Brinc later supported portfolio reporting that included SmartPeep

Context & qualifications

The hospital report and study document SmartPeep's activity at specific sites. They help explain how a health technology can be adopted. They do not establish paid international sales, current contracts or participation in the proposed programme.

12Healium Digital: a Singapore chronic-disease example

Singapore company in the 2021 Brinc / Future Health Asia cohort

Portfolio description focuses on non-invasive early detection and management of chronic kidney disease

Relevant to preventive population health and healthy longevity

Programme application | Test clinical use, evidence needs and a viable adoption pathway

Context & qualifications

Healium’s inclusion in the documented cohort establishes the programme relationship. Its described focus is relevant to Precision Health. Regulatory status, accuracy and hospital deployments would need company-specific evidence before being stated.

13Sova Health: gut health and personalised nutrition

Brinc portfolio example in gut microbiome testing and personalised nutrition

Source records operations in India and incorporation in Singapore

Services described include testing, coaching and personalised supplements

Programme application | Evaluate evidence, consumer needs and repeatable commercial delivery

Context & qualifications

Sova is a portfolio example relevant to gut health and personalised nutrition. The sources distinguish incorporation in Singapore from operations in India. They do not establish Singapore sales or therapeutic-product approval.

Healthcare evidence

45Healthcare examples: products, evidence and adoption

Zeta Surgical | Device-specific surgical navigation clearances

Strados Labs | Respiratory sound recording devices

Frontier Bio | Tissue-engineered research models

Jetbrain | Hospital logistics robotics

SmartPeep | Hospital monitoring implementations and studies

Context & qualifications

These historical portfolio examples show different product, evidence, adoption and strategic pathways. They are not the membership list for the active 197-company snapshot. Company milestones belong to the companies; Brinc’s documented contribution is stated separately.

46Altris AI: ophthalmic imaging and the 2021 MedTech cohort

Participant in the 2021 Brinc / Future Health Asia MedTech cohort

Altris IMS received FDA clearance in July 2023 for image management and manual annotation

The cleared software’s intended use is device-specific

Programme application | Align product claims, evidence and customer adoption

Context & qualifications

FDA K232088 specifies that the cleared image-management software does not use AI or machine-learning algorithms and does not provide diagnoses or treatment recommendations. The company’s separate AI capabilities should remain distinct from this clearance. Brinc’s cohort role is separate from the company’s regulatory achievement.

47Zeta Surgical: navigation devices and regulatory milestones

Brinc portfolio example

Cranial navigation technology for neurosurgical workflows

FDA records document cranial navigation clearance in 2023

The company announced TMS navigation clearance in 2025

Relevant lesson | Tie commercial planning to device-specific evidence

Context & qualifications

Clearance applies to the specified devices and intended uses. A historical plan for a Singapore study is distinct from evidence that it took place. The case illustrates how development and adoption milestones shape venture support.

48Strados Labs: respiratory recording devices

Brinc portfolio example

RESP records adult lung sounds

FDA records cover healthcare-setting and subsequent outpatient use

Commercial work must address users, care settings and adoption

Relevant lesson | Match the venture plan to the device’s permitted use

Context & qualifications

A venture needs a precise account of the product, evidence and intended care setting. That precision helps identify the right clinical partners, buyers and development priorities.

49Frontier Bio: engineered tissue models and research collaboration

Brinc portfolio example

Engineered tissue models for research and testing

Publicly described blood-vessel proof of concept with Mayo Clinic

Additional work on neural and lung tissue models

Relevant lesson | Define the application and validation pathway

Context & qualifications

The cited work establishes a specific research collaboration and proof of concept. It provides an example for assessing applications, validation needs and the commercial proposition of research-intensive ventures.

50Hospital examples and the activity documented

Parkway East Hospital | SmartPeep implementation, Singapore

Hospital Seberang Jaya | SmartPeep pilot study, Malaysia

Houston Methodist | M&S Biotics research relationship in the portfolio source

Mayo Clinic | Frontier Bio proof of concept

Context & qualifications

These examples identify the institutions in the available evidence. Their activities differ: implementation, pilot study and research relationships are reported separately. Revenue and current commercial contract status require separate confirmation.

51Evidence of international activity, company by company

Record the company’s home market and target market

Identify the named institution, buyer or partner

Distinguish operations, studies, pilots and customer contracts

Capture evidence date and the next commercial milestone

Context & qualifications

The available sources establish company-specific implementation, research and regulatory activity, not a verified aggregate of paid overseas customers. Country tags denote headquarters or presence. A partial review of 22 multi-country-tagged companies, including six classed as selling or operating internationally, does not establish an exporter count. The three Healthcare-tagged companies in that selected set have no market information found; that is not evidence of zero sales. A paid-sales register needs company, home market, customer market, period, contract or revenue evidence and source date.

International experience

52Relevant Hong Kong experience and relationships

Hospital Authority | Health IT dialogue

CityUHK | Entrepreneurship programme delivery

HKSTP | Landing cohorts and ecosystem matching

Manulife | Startup selection and proof-of-concept design

Health innovation convening | Asia Health Innovation Summit

Context & qualifications

These Hong Kong examples show services and relationships that can inform venture support. Re-engagement would be tied to a Singapore venture’s specific need and the counterpart’s interest.

53Hospital Authority: Health IT discussions

Brinc presented to the Institute of Health IT in January 2026

Subsequent discussions explored Health IT collaboration themes

The dialogue provides an existing relationship to revisit

Relevant lesson | Start with a defined problem and responsible counterpart

Context & qualifications

Brinc’s relationship includes a presentation and follow-up discussion. For a programme venture, the next step would be to assess fit with the appropriate team and agree any further engagement.

54CityUHK: entrepreneurship programme delivery

Brinc delivered an eight-week programme for HK Tech 300’s first cohort

Work covered team formation, validation and venture readiness

Further delivery is supported by 2022 correspondence

CityUHK referred venture teams to Brinc in 2026

Context & qualifications

The case illustrates practical founder-development work and a university relationship that continued through later referrals. The delivery methods can inform the formation track, with health expertise added for Precision Health.

55HKSTP: two startup landing cohorts

Brinc operated two 2021 landing cohorts

Activities included recruitment, screening and market-entry workshops

Teams received investor and ecosystem matching with follow-up

Singapore’s MyrLabs participated in the second cohort

Context & qualifications

This is an operating precedent for the optional Singapore recruitment workstream. Candidate interest, programme attendance and established local operations should be tracked as successive milestones.

56Manulife BOOST: startup selection and proof-of-concept planning

Manulife publicly named Brinc as its 2021 BOOST partner

Selected companies included Pulse Active Stations, OME Health and Planner Bee

Manulife and Brinc scoped proofs of concept around corporate use cases

Relevant lesson | Shape startup engagement around a corporate use case

Context & qualifications

The public 2021 announcement documents the partnership, selected companies and proof-of-concept scoping. It illustrates corporate selection and pilot preparation, not completed pilots or paid sales.

57Asia Health Innovation Summit: bringing the health ecosystem together

Brinc hosted its fourth Asia Health Innovation Summit in October 2024

The event formed part of InvestHK’s StartmeupHK Festival

Participants included health, technology and ecosystem leaders

Relevant lesson | Convene specialists around venture and market needs

Context & qualifications

The proposed community programme builds on experience convening relevant people. Its follow-up would be organised around the needs of participating ventures and documented next actions.

58Jetbrain: accelerator support and the Solaris acquisition

Hong Kong Fall 2018 Hardware and IoT accelerator participant

Brinc described prototype, manufacturing and founder support

Solaris announced its acquisition in August 2020

Hospital logistics robotics provides a healthcare operations example

Context & qualifications

Jetbrain’s transport robotics and Solaris’ disinfection technology have separate product histories. The documented acquisition is a dated company outcome that illustrates one possible path for a supported venture.

59Further Hong Kong relationships to assess

CUHK | Venture introduction and expansion discussion

Cyberport | Founder referrals and programme-support pathways

PolyU | Co-acceleration programme design

HKTDC | Investment mentoring at ASGH

Context & qualifications

The relationship owner would assess which route suits each venture. These examples cover different levels of engagement, from referral to programme design and mentoring.

60Research commercialisation and growth experience in the Middle East and North Africa

NYU Abu Dhabi / startAD | Health and wellbeing innovation work

Khalifa University / ADGM Academy | TRL Bridging support

MBRIF | Government-backed venture growth

Monsha’at / BIM Ventures | Cross-border soft landing

Context & qualifications

These cases provide additional operating experience and potential routes for venture-specific market discussions. The Singapore programme remains anchored in the selected portfolio and the agencies’ priorities.

61startAD: innovation work with health and wellbeing organisations

Brinc delivered the AI Readiness Track for the 2025 AI for Good programme

Work covered needs assessment, challenge definition and solution evaluation

Workshops developed potential pilot roadmaps

Participants included organisations in the UAE and Saudi Arabia

Context & qualifications

The detailed programme report supports workshops and pilot planning. This is useful experience for translating an organisation’s needs into a practical engagement with innovative solutions.

62Health organisations that contributed to the readiness work

Ability Pediatric Rehabilitation Medical Center participated in the readiness work

National Multiple Sclerosis Society contributed programme challenges

Saudi Arabia’s National Center for Mental Health Promotion contributed challenges

Relevant lesson | Start from an institution’s defined care or service need

Context & qualifications

These are historical programme participation examples. They show experience working with organisations on specific needs and preparing a basis for solution evaluation.

63TRL Bridging: research commercialisation workshops and mentoring

Brinc supported commercialisation workshops and individual mentoring

The programme brought research teams into industry engagement

ADGM Academy’s fair included Health and Life Sciences

Relevant lesson | Build market and team readiness alongside technology development

Context & qualifications

The case is relevant to the local formation track. It supports Brinc’s experience with commercialisation readiness, while each research project retains its own technical and institutional decision process.

64MBRIF: government-backed startup acceleration

Brinc’s work with MBRIF supports startup acceleration

The initiative’s remit includes health among other sectors

Healthcare claims technology company KLAIM.AI appears among alumni

Relevant lesson | Combine commercial support with ecosystem connections

Context & qualifications

The case illustrates a government-supported growth model combining practical venture support and access to relevant organisations. Its historical programme metrics do not become targets for the Singapore proposal.

65Monsha’at and BIM Ventures: Saudi-to-UAE market-entry support

Brinc supported Saudi scaleups exploring the UAE market

Activities covered market-entry strategy and commercial preparation

Companies received curated ecosystem introductions

Relevant lesson | Pair recruitment with structured landing support

Context & qualifications

The optional Singapore workstream could use similar methods for market-entry preparation and introductions. The programme would agree what counts as local presence and progress towards establishment for each selected company.

66Further Middle East and North Africa relationships to assess

Tamkeen | Startup and enterprise innovation programmes

Hub71 | Existing Brinc operating relationship

Hub71 Life Sciences | Potential route for relevant future engagement

NEOM / Oxagon | Cross-sector corporate pilot preparation

Context & qualifications

The broader network can be considered when a venture has a defined market or partner need. Access and programme participation would be established through the appropriate relationship owners.

Next steps

41Agree the Sprint brief, then mobilise the programme

Review the healthcare evidence and proposed scope together

Confirm proposed co-organiser roles, referral criteria and institutional decision owners

Agree authorised pipeline access, A*STAR's Sprint procurement and signing arrangements, and a workable timetable

Hold a joint call, followed by an in-person working session in Singapore

Context & qualifications

The next call should settle the remaining scope and evidence questions. The in-person session can then agree the Sprint brief, responsible leads and steps towards mobilisation.

71Decisions for the joint working session

Portfolio volume and Singapore referral criteria

A*STAR’s Sprint procurement route, signatory, mobilisation date and review owners

Named delivery roles and institutional decision owners

Evidence requirements and first-quarter priorities

Next working session and accountable actions

Context & qualifications

The working session will settle the arrangements needed to start the Sprint. Each agreed action will have an owner and review date.

Prefer the slide deck?

Download the 79-slide deck ↓